The pharmacogenetics of chemical carcinogenesis
| Autor: | Jeffrey R Idle, Martin Armstrong, Alan V. Boddy, Carol Boustead, Suzanne Cholerton, Jane Cooper, Ann K Daly, Janice Ellis, Wendy Gregory, Hakam Hadidi, Constance H??fer, John Holt, Julian Leathart, Nigel McCracken, Sophia C Monkman, John E. Painter, Heather Taber, Dianne Walker, Murray Yule |
|---|---|
| Předmět: |
Disease
Biology medicine.disease_cause Xenobiotics law.invention chemistry.chemical_compound Cytochrome P-450 Enzyme System law Neoplasms Genetics medicine Animals Humans General Pharmacology Toxicology and Pharmaceutics Polymerase chain reaction Polymorphism Genetic Phenotype chemistry Scientific development Carcinogens Oxygenases Metabolic phenotype Carcinogenesis Xenobiotic Pharmacogenetics |
| Zdroj: | Scopus-Elsevier |
| Popis: | The human body is endowed with a large number of xenobiotic chemical metabolizing enzymes, a significant proportion of which are polymorphic and thus render one individual at greater or lesser risk than another of chemically-induced disease. All examples of genetic polymorphism of chemical metabolizing enzymes have been reviewed in relation to their potential to activate and detoxicate procarcinogens and promutagens. Many examples are cited whereby phenotype can act as a carcinogenic risk factor. With the availability of a large amount of DNA sequence data for chemical metabolizing enzymes there has emerged a number of polymerase chain reaction (PCR) strategies aimed at discerning one metabolic phenotype or another. This is seen as a very positive and democratic scientific development, widening the franchise for studies of disease risk. Nevertheless, it is argued that, at these early stages with many laboratory-based scientists scarcely familiar with epidemiological study design, a cautious approach should obtain when interpreting single studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|